People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inmune Bio, Inc. | — | Biotechnology | Series A | $8.0M | $169.9M | 2017 |
J. Kelly Ganjei at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside J. Kelly Ganjei on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Raymond J. Tesi | 1 | 2 |
| David J. Moss | 1 | 1 |
| Mark J. Lowdell | 1 | 1 |
| Timothy Kelly Schroeder | 1 | 1 |
| David Kelly Szymkowski | 1 | 1 |
| Scott Kelly Juda | 1 | 1 |
| Terry R. Knapp | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.